Australia markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.5700+0.0900 (+3.63%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4800
Open2.4800
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's range2.3900 - 2.5700
52-week range2.3900 - 6.8800
Volume79,900
Avg. volume240,658
Market cap113.559M
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)-1.2980
Earnings date27 Oct 2021 - 01 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.52
  • InflaRx to Present at the Raymond James Human Health Innovation Conference
    GlobeNewswire

    InflaRx to Present at the Raymond James Human Health Innovation Conference

    JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the Raymond James Human Health Innovation Conference being held June 21-23, 2021. A Raymond James analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the Company’s pipeline and upcoming catalysts on Wedn

  • InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
    GlobeNewswire

    InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

    Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the enrollment of the first patient in an open-label, multicenter Phase II clinical study evaluating vilobelimab alone and in combination with pembrolizumab in patients with PD-1 or PD-L1 inhi

  • We're Hopeful That InflaRx (NASDAQ:IFRX) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That InflaRx (NASDAQ:IFRX) Will Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...